Overcoming resistance mechanisms in a study of cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).

被引：0
|
作者：
Karzai, Fatima
Madan, Ravi Amrit
Theoret, Marc Robert
Arlen, Philip M.
Strauss, Julius
Chun, Guinevere
Couvillon, Anna
Harold, Nancy
Chen, Clara
Dawson, Nancy Ann
Apolo, Andrea Borghese
Steinberg, Seth M.
Trepel, Jane B.
Wright, John Joseph
Price, Douglas K.
Gulley, James L.
Figg, William Douglas
Dahut, William L.
机构：
[1] NCI, NIH, Bethesda, MD 20892 USA
[2] NCI, Bethesda, MD 20892 USA
[3] NCI, Med Oncol Branch, NIH, Bethesda, MD 20892 USA
[4] NCI, Genitourinary Malignancies Branch, NIH, Bethesda, MD 20892 USA
[5] NIH, Dept Nucl Med, Ctr Clin, Bethesda, MD USA
[6] Lombardi Comprehens Canc Ctr, Washington, DC USA
[7] NCI, Biostat & Data Management Sect, NIH, Bethesda, MD 20892 USA
[8] NCI, Dev Therapeut Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[9] NCI, Mol Pharmacol Sect, NIH, Bethesda, MD 20892 USA
[10] NCI, Clin Pharmacol Program, NIH, Bethesda, MD 20892 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e16032
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16032
引用
收藏
页数：1
相关论文
共 50 条
  • [41] The role of macrophages in docetaxel (DTX) resistance in castrate-resistant prostate cancer (CRPC).
    Horvath, Lisa
    Chatfield, Mark D.
    Lee-Ng, Michelle
    Lin, Hui-Ming
    Castillo, Lesley
    Breit, Samuel N.
    Brown, David A.
    Molloy, Mark P.
    Marx, Gavin M.
    Pavlakis, Nick
    Boyer, Michael J.
    Stockier, Martin R.
    Wykes, Richard
    Henshall, Susan M.
    Mahon, Kate Lynette
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [42] A phase II study of docetaxel plus lycopene in metastatic castrate resistant prostate cancer
    Zhuang, Eric
    Uchio, Edward
    Lilly, Michael
    Zi, Xiaolin
    Fruehauf, John P.
    BIOMEDICINE & PHARMACOTHERAPY, 2021, 143
  • [43] Real-world evidence in patient-related outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate plus prednisone (AA plus P).
    Gotto, Geoffrey
    Fradet, Vincent
    Drachenberg, Darrel
    Sabbagh, Robert
    Rendon, Ricardo A.
    Shayegan, Bobby
    Danielson, Brita Lavender
    Casey, Richard
    Chan, Katherine
    Camacho, Fernando
    Zardan, Anousheh
    Hew, Huong
    Feifer, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [44] Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer
    Heath, Elisabeth
    Heilbrun, Lance
    Mannuel, Heather
    Liu, Glenn
    Lara, Primo
    Monk, J. Paul
    Flaig, Thomas
    Zurita, Amado
    Mack, Philip
    Vaishampayan, Ulka
    Stella, Philip
    Smith, Daryn
    Bolton, Susan
    Hussain, Arif
    Al-Janadi, Anas
    Silbiger, Daniel
    Usman, Muhammad
    Ivy, S. Percy
    ONCOLOGIST, 2019, 24 (09): : 1149 - +
  • [45] Efficacy and toxicity of docetaxel in elderly men with castrate-resistant metastatic prostate cancer.
    Shepard, D. R.
    Weil, A.
    Garcia, J. A.
    Dreicer, R.
    Raghavan, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [46] Genomic landscape of CDK12 mutated metastatic castrate-resistant prostate cancer (mCRPC).
    Grivas, Petros
    Bratslavsky, Gennady
    Jacob, Joseph M.
    Necchi, Andrea
    Spiess, Philippe E.
    Danziger, Natalie
    Huang, Richard
    Mata, Douglas A.
    Decker, Brennan James
    Sokol, Ethan
    Montesion, Meagan
    Tukachinsky, Hanna
    Venstrom, Jeffrey Michael
    Ross, Jeffrey S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [47] KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
    Kolinsky, Michael Paul
    Gravis, Gwenaelle
    Mourey, Loic
    Piulats, Josep M.
    Sridhar, Srikala S.
    Romano, Emanuela
    Berry, William R.
    Gurney, Howard
    Retz, Margitta
    Appleman, Leonard Joseph
    Boegemann, Martin
    De Bono, Johann S.
    Joshua, Anthony M.
    Emmenegger, Urban
    Conter, Henry Jacob
    Laguerre, Brigitte
    Wu, Helen
    Schloss, Charles
    Poehlein, Christian Heinrich
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [48] Updated analysis of a phase II study using sorafenib (S) for metastatic castrate-resistant prostate cancer (mCRPC)
    Aragon-Ching, J. B.
    Jain, L.
    Draper, D.
    Gulley, J. L.
    Arlen, P. M.
    Wright, J. J.
    Jones, E.
    Chen, C. C.
    Figg, W. D.
    Dahut, W. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [49] Comparison of survival of African-American (AA) patients (pts) in docetaxel (D)-based combination therapies in metastatic castrate-resistant prostate cancer (mCRPC).
    Karzai, Fatima
    Madan, Ravi Amrit
    Ning, Yang-Min
    Theoret, Marc Robert
    Arlen, Philip M.
    Parnes, Howard L.
    Ojemuyiwa, Michelle A.
    Strauss, Julius
    Dawson, Nancy Ann
    McLeod, David G.
    Harold, Nancy
    Couvillon, Anna
    Cordes, Lisa M.
    Chen, Clara
    Steinberg, Seth M.
    Sissung, Tristan M.
    Price, Douglas K.
    Gulley, James L.
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [50] A prospective trial of apalutamide and abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer
    George, Daniel J.
    Halabi, Susan
    Fleming, Mark T.
    Heath, Elisabeth I.
    Tutrone, Ronald F.
    Sutton, Linda
    Whang, Young E.
    Lewis, Brian E.
    Humeniuk, Michael Sandon
    Berry, William R.
    Harrison, Michael Roger
    Hurrelbrink, Julia
    Shobe, Kellie
    Rasmussen, Julia
    Anand, Monika
    Reyes-Martinez, Marco
    Howard, Lauren
    Patierno, Steven R.
    Freedman, Jennifer A.
    Armstrong, Andrew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345